Erythro-hydroxynonyladenine analogs with enhanced lipophilic...

Details Erythro-hydroxynonyladenine analogs with enhanced lipophilic... Erythro-hydroxynonyladenine analogs with enhanced lipophilic...

A - Human Necessities

61

K

A61K 31/52 (2006.01)

Patent

CA 2199615

Analogs of erythro-hydroxynonyladenine (EHNA) are disclosed which have been modified by bonding various types of moieties to the #8 or #9 carbon atoms in the "side chain" portion of the molecule. The compounds inhibit the intracellular enzymatic activity of adenosine deaminase and are therapeutically effective in reducing hypoxic and ischemic damage in heart and brain tissue.

Analogues d'érythro-hydroxynonyladénine (EHNA) qui ont été modifiés par la liaison de divers types de fractions aux atomes de carbone en position 8 ou 9 dans la partie chaîne latérale de la molécule. Ces composés inhibent l'activité enzymatique intracellulaire de l'adénosine désaminase et réduisent efficacement, sur le plan thérapeutique, les lésions ischémiques et hypoxiques des tissus du coeur et du cerveau.

Affiliated with

Also associated with

Rating

Erythro-hydroxynonyladenine analogs with enhanced lipophilic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Erythro-hydroxynonyladenine analogs with enhanced lipophilic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythro-hydroxynonyladenine analogs with enhanced lipophilic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1624072